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Abstract
Objective: Rhythm abnormalities following transcatheter aortic 
valve implantation (TAVI) and indications for permanent pacemaker 
implantation (PPI) were reviewed, which aren’t well established 
in the current guidelines. New left bundle branch block and 
atrioventricular block are the most common electrocardiographic 
changes after TAVI. PPI incidence ranges from 9-42% for self-
expandable and 2.5-11.5% for balloon expandable devices. Not 
only anatomical variations in conduction system have an important 
role in conduction disorders, but different valve characteristics 
and their relationship with cardiac structures as well. Previous 
right bundle branch block has been confirmed as one of the most 
significant predictors for PPI.
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INTRODUCTION
Increased life expectancy has contributed to making cardiac 
valve diseases more frequent and relevant[1]. 
Aortic valve stenosis (AoS), the most common cardiac valve 
disease, affects approximately 3% of the population older than 
75 years[2] and, usually, remains silent for many years. 
However, once symptoms are present, survival decreases 
dramatically[3,4], being surgical treatment the therapy of choice[5].
Since the first clinical report in 2002, transcatheter aortic valve 
implantation (TAVI) has emerged as a valuable, less invasive and safe 
therapeutic alternative in patients with symptomatic severe AoS[6]. 
Currently, TAVI is considered the gold standard for high-risk 
patients, the only option for inoperable ones, and, recently, non-
inferior to conventional surgery in intermediate risk patients[7-9]. 
On the other hand, this is not a risk-free procedure, with 
atrioventricular (AV) conduction disturbances being a common 
complication[10]. 
In this context, understanding post-procedural conduction 
disturbances’ mechanisms and rates is an extremely current and 
relevant issue.  
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In the post-TAVI phase, the management depends on the 
prosthesis implanted. For instance, early removal of the temporary 
pacing lead seems to be safe after the balloon expandable 
Edwards Sapien® prosthesis, in the absence of intraprocedural 
advanced degree blocks. Then, a 24-48 hour electrocardiographic 
monitoring followed by a daily 12-leads electrocardiogram (ECG) 
until the discharge is recommended. On the contrary, when a 
self-expandable CoreValve® prosthesis is chosen, a 48-72 hour 
monitoring before removal of the temporary pacing lead might 
be recommended even when the ECG early after TAVI is normal[19].
QRS duration is another factor that may assist the decision 
about early or late pacing lead removal. According to a Takahashi’s 
et al.[20] study, in which patients with QRS duration <120 ms were 
submitted to early pacing lead removal and those with QRS ≥120 
ms to late removal, no PPI was indicated in the first group, while 
39% of the latter developed a delayed AVB (P=0.0001).  
Taking into account that TAVI is routinely performed under 
heparin anticoagulation, which potentially may lead to an 
increased bleeding rate for PPI immediately after TAVI, Schwerg 
et al.[21] evaluated patients who have undergone PPI implantation 
on the same day of TAVI implant (group A) and patients in whom 
the PPI was performed at least 1 day after TAVI (group B) (3.8±4.5 
days). In this study, procedure times, fluid loss via drainage 
systems, and drainage times were neither significantly different 
between the groups nor when compared to a historical group.
 
PPI Risk Factors
Many factors have been identified for PPI requirement after 
TAVI, mainly related to baseline conductions defects, device 
selection and anatomical characteristics[22]. Thus, a careful pre-
TAVI screening is overwhelming important[19].  
Advanced age, permanent atrial fibrillation, use of digoxin, 
larger or oversized prosthesis[23,24], for example, are considered 
clinical predictors for new LBBB post-TAVI, while left heart axis, 
lower mean heart rate, and prolonged PQ and QRS times are 
considered electrocardiographic parameters for severe cardiac 
conduction defects requiring PPI in patients with new LBBB[24]. 
During the procedure predilatation and valve deployment are 
the most critical steps for conduction disorders development[25,26].
Regarding the available devices, the differences in shape, 
height of the frame, depth of implantation and different physical 
properties account for the different PPI incidences observed[19]. 
A meta-analysis published in 2014 with 41 studies comprising 
11210 post-TAVI patients, showed an unadjusted 2.5-fold higher 
risk for CoreValve® (28%) compared to Sapien® (6%). The risk was 
increased for men [relative risk (RR) 1.23; P<0.01]; previous first-
degree AVB (RR 1.52; P<0.01), LAHB (RR 1.62; P<0.01) or RBBB (RR 
2.89; P<0.01) and intraprocedural AVB (RR 3.49; P<0.01)[27].
This study aims to review rhythm abnormalities after TAVI, 
besides the permanent pacemaker implantation (PPI) indications, 
which are not well established by the current guidelines.
Rhythm Abnormalities
Bradyarrhythmias are not uncommon after cardiac surgery, 
TAVI and heart transplantation. According to the 2013 European 
Society of Cardiology guidelines on cardiac pacing and cardiac 
resynchronization therapy[11], complete atrioventricular block 
(AVB) may occur in 1-4% of cardiac surgeries, 8% of repeat valve 
surgeries and up to 20-24% of interventions for calcified AoS or 
tricuspid valve replacement. 
Following TAVI, new left bundle branch block (LBBB) and AVB 
are the main electrocardiographic changes and the consequent 
need for a permanent pacemaker is the most expensive short-
term adverse event[12]. 
The incidence of post-procedural conduction disturbances 
varies among studies, being 20% in complete AVB, 7% to 83% 
in LBBB, 2% in right bundle branch block (RBBB) and 2% in left 
anterior hemiblock (LAHB)[13-16].
By Urena et al.[13], 37.7% of these new LBBB are resolved before 
hospital discharge and 57% in 6-12-month follow-up period. 
The PARTNER trial analysis showed that, although new LBBB 
has not been associated with increased 1–year mortality, it was 
associated with a higher in-hospital pacemaker indication [8.3% 
versus 2.8%; P=0.005] and from discharge to one year (4.7% vs. 
1.5%; P=0.01), as well as failure to improve left ventricular ejection 
fraction (52.8 vs. 58.1%; P<0.001)[17]. 
In contrast, another study showed new LBBB as an independent 
predictor of all-cause mortality [hazard ratio (HR) 1.54; 95% confidence 
interval (CI) 1.12 – 2.10]. Cardiovascular mortality rate was 9.4% for 
patients without TAVI-induced LBBB and 18% for new LBBB[15]. 
Similarly, for Makki et al.[18], PPI has been associated with increased 
short- and long-term mortality, which may represent inherent 
conduction abnormality or pacemaker operation morbidity. 
PPI Indications
Pacemaker implantation after TAVI has had the same 
recommendations as non-surgical patients with persistent 
bradycardia, such as symptomatic bradycardia, complete AVB, 
type II second-degree AVB, new LBBB in combination with infra-
hisian conduction delay (HV interval ≥70 ms or second or third-
degree Hiss-Purkinje block)[11]. 
The 2013 European Society of Cardiology guideline considers 
indication class I, level C “high degree or complete AVB after 
cardiac surgery and TAVI, with a period of clinical observation up 
to 7 days (Table 1). In case of complete AVB with a low rate of 
escape rhythm, this observation period can be shortened since 
the resolution is unlikely”[11].
Table 1. Recommendation for pacing after transcatheter aortic valve implantation[11].
Recommendation Class of recommendation Level
I) High degree or complete AV block after TAVI I C
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A cut-off value of 6 mm predicted this need with a sensitivity of 
89% and specificity of 40%.
Nuis et al.[25] also reported a direct relationship between 
the balloon/annulus ratio during balloon valvuloplasty and the 
development of new conduction disturbance, with a balloon/
annulus ratio close to 1.0 as an acceptable compromise to avoid it.
PPI Rates
PPI after TAVI incidence has been reported ranging from 9% 
to 42% for self-expandable valves (CoreValve®) and from 2.5% to 
11.5% for balloon expandable valves (Edwards Sapien®)[34].
In the Partner 2 trial, where the Sapien XT® system was used 
in patients with severe AoS and intermediate surgical risk, the 
30-day PPI rate was 8.5%[7]. 
Comparing two generations of self-expanding repositionable 
valves, the PPI rates were 25.5% for CoreValve® and 26.7% for the 
new generation Evolut R®[8]. 
In the CHOICE trial, a lower 30-day pos-procedural PPI need 
was observed in the balloon-expandable group (Sapien XT®) 
when compared to the self-expandable group (CoreValve®) 
(17.3% vs. 37.6%, RR 0.46, 95% CI 0.28 – 0.74). Besides, 
cardiovascular mortality within 30 days was 4.1% in the first and 
4.3% in the second group (RR 0.97, 95% CI 0.29 – 3.25; P=0.99)[35].
Another study comparing second generation devices - 
Direct Flow Medical®, Lotus®, Evolut R® or Sapien 3® (2G) to first 
generation - Sapien XT®, CoreValve® (1G), showed no differences 
regarding PPI requirement (6.5% vs. 7.8%; P=0.46); but patients 
treated with 1G devices suffered more 30-day adverse events 
(free of adverse events 75.3% vs. 88.8%, HR 2.4; 95% CI 1.4 – 4.0; 
P=0.01)[36].
According to access routes, The German aortic valve registry 
(GARY), the biggest registry about TAVI, showed that 1-year 
pacemaker need was 26.2% in transvascular approach and 14.1% 
in transapical[37]. 
Finally, in a meta-analysis published in 2016, which compared 
TAVI with conventional SVAR in low and intermediate risk patients, 
a higher PPI rate after TAVI was observed when compared to 
SAVR (21.6% vs. 7.5%, OR 7.4, 95% CI 1.98 – 8.34; P<0.001)[38]. The 
same finding has not been seen with sutureless devices, which 
have a PPI incidence similar to TAVI (5-17%)[39-42].
 
CONCLUSION
Not only anatomical variations in each patient conduction 
system may have an important role in the conduction disorders 
prevalence after TAVI, as well as the different valve implanted 
and its characteristics in terms of diameter and relationship with 
other cardiac structures. Self-expandable devices are related to 
a higher incidence of PPI need than balloon-expandable valves.
Some baseline features, like RBBB, have been confirmed as 
significant predictors of PPI need. Moreover, new LBBB, which 
most often occur in the first 48 hours after TAVI, may also be a 
PPI risk factor.
Further studies may be necessary for better understanding of 
rhythm abnormalities and to establish the permanent pacemaker 
implantation criteria after TAVI.
In a more recent study, the combination of pre-TAVI prolonged 
PR interval (>220 ms) and increased QRS duration (>120 ms) 
reached a positive predictive value for PPI of 80%, suggesting to 
use such parameters as periprocedural PPI markers[28]. 
Analyzing national data, the Brazilian Registry of 418 patients 
with severe AoS who had undergone TAVI demonstrated a 
30-day PPI incidence of 25.2%. On multivariable analysis only 
CoreValve® vs. Sapien XT® [odds ratio (OR) 4.24, 95% CI 1.56 
– 11.49; P=0.005], baseline RBBB (OR 4.41, 95% CI 2.20 – 8.82; 
P<0.001), and balloon pre-dilatation (OR 1.75, 95% CI 1.02 – 3.02; 
P=0.04) were independent PPI predictors[29].  
Supporting these data, solely baseline RBBB and deep valve 
implantation were found as predictors of high-degree AVB and 
PPI requirement in a separate multivariable analysis of a study 
published in 2011 in the American Journal of Cardiology[30].
In terms of potential tools for AVB risk stratification in the 
electrophysiological study (EPS), a cohort led by Kostoupoulou 
et al.[16] analyzed 30 patients who underwent EPS, 25 of these 
had a second EPS after 48h. Delta-HV did not show to be a risk 
factor and baseline HV interval did only in univariate analysis. 
Opposing these findings, physicians from the Montreal Heart 
Institute followed 75 patients who had undergone EPS before 
and after TAVI. In multivariate analysis, the delta-HV interval 
was independently associated with AVB development and its 
sensitivity and specificity for predicting AVB were, respectively, 
100% and 84.4% for a delta-HV interval ≥13ms[31]. 
Considering the left ventricular outflow tract (LVOT) in 
terms of amount of calcium, perimeter and device size relative 
to LVOT, as well as the degree of valve protrusion into the LVOT, 
once these factors could affect the underlying conduction 
system, Rodríguez-Olivares et al.[32] performed a study where 
computed tomography was used to assess LVOT. By multivariate 
analysis RBBB at baseline (OR 2.9, 95% CI 1.2 – 6.9; P=0.014), 
next generation valves (OR 2.1, 95% IC 1.0–4.5; P=0.048), depth 
of implantation (OR 1.2 per 1 mm increment, 95% IC 1.1–1.3; 
P<0.001) and LVOT sizing (OR per 1% increment 1.0, 95% IC 1.0–
1.06; P=0.022) were predictors of PPI.
Heart Block Mechanisms after TAVI
By Young Lee et al.[10] inter-individual variation in the 
penetrating bundle length and depth of septal penetration and 
variation in the location of the proximal portion of left bundle 
determine how susceptible these structures are to injury during 
TAVI. 
While conduction abnormalities in surgical aortic valve 
replacement (SARV) are attributed to the surgical method – 
suturing along the sewing ring near the membranous septum, 
removal of the native aortic valve and edema – the susceptibility 
to AVB in TAVI is more specific. 
In CoreValve®, the AVB risk is partly due to the valve design 
and the potential for a deeper valve implantation into the 
LVOT[10].
Kammler et al.[33] identified that the mean distance from 
the annular margin of the non-coronary cusp to the ventricular 
end of the prosthesis was significantly longer in patients with 
pacemaker requirement (9.7±4.1 mm vs. 6.3±3.4 mm; P=0.0017). 
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